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INTRODUCTION
57
Lersivirine is a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) of 58 human immunodeficiency virus (HIV)-1 that displays potent antiviral activity against 59 wild-type virus and also against certain clinically-relevant NNRTI-resistant viruses (23).
60
X-ray crystallography has demonstrated that lersivirine binds to the reverse transcriptase in a 61 novel way, which is thought to contribute to antiviral activity against key class resistant 62 mutants, such as K103N, Y181C, and G190A (5,28). However, the mechanism of lersivirine Lersivirine is metabolized by CYP3A4 and uridine diphosphate glucuronosyltransferase 67 (UGT)2B7; it is also a weak inhibitor of glucuronidation (10,35). Lersivirine has been shown 68 to be a weak inducer of CYP3A4 activity at clinical doses (9) and, based on in vitro data, is 69 an inhibitor and substrate for P-glycoprotein (P-gp) (Pfizer Inc., data on file). However, 
82
Rifabutin is metabolized and eliminated mainly by the CYP3A pathway and is a moderate 
87
As an estimated one-third of individuals living with HIV infection are co-infected with 88 tuberculosis (37), it is important that treatments in development are compatible for co-89 administration (11). This manuscript reports the findings from two pharmacokinetic (PK) 90 studies, of similar design, of the anti-tuberculosis agents rifampicin and rifabutin when each 91 is co-administered with lersivirine.
92
The objective of Study 1 (Study A5271008) was to investigate the effects of rifampicin on 6 
METHODS
99
Subjects
100
Eligible subjects were healthy males aged 21 to 55 (Study 1) or healthy male/female subjects 101 aged 18 to 55 (Study 2), who had a body mass index (BMI) of 18-30 kg/m 2 (Study 1) or 102 17.5-30.5 kg/m 2 (Study 2) and a total body weight of >45 kg (Study 1) or >50 kg (Study 2).
103
Subjects with a history of significant disease, HIV or hepatitis B or C were excluded.
104
Prescription and non-prescription drugs, vitamins and dietary supplements medications were 105 not permitted during the study and had to be discontinued within 7 days or 5 half-lives (which 106 was longer) prior to the first dose of study medication. was examined following dosing to assure that the study medication was taken.
107
Study Designs
134
Sampling and Analytical Methods
135
In Study 1, blood samples were collected on Days 1, 9, 11 and 13 at 0 hours (predose), on 
140
In Studies 1 and 2, blood samples of 5 mL and 4 mL, respectively, were taken to provide a 
Statistical Analyses
179
The PK parameters AUC 24 , plasma concentration observed at 24 hours postdose (C 24 ), C max ,
180
and time to C max (T max ) were summarized by treatment. An adhoc analysis was performed to 181 assess the elimination half-life (T½) for lersivirine in the presence of rifampicin and rifabutin.
182
AUC parameters were determined using the linear/log trapezoidal method and C max , C 24 , and
183
T max were determined by observation. Natural log transformed data were analyzed using a 184 mixed-effect model with sequence, period, and treatment as fixed effects, and subject within 185 sequence as a random effect. The adjusted geometric mean for each treatment was obtained
186
by exponentiation of the mean estimate on the natural log scale obtained from the model.
187
Estimates of the adjusted mean differences (Test/Reference) and corresponding 90% CIs 
193
RESULTS
194
Subjects
195
All the 17 subjects in Study 1 were Asian males. The majority of subjects in Study 2 were (Table 3A) .
214
The rifabutin concentration profile or overall exposure did not change following rifabutin, was observed (Table 3B ; Figure 3 ).
218
Safety
219
There were no deaths, serious AEs or severe AEs, dose reductions, or temporary 220 discontinuations due to AEs in either study. AEs that occurred in more than two subjects are 221 summarized by study and treatment group in decreased by 80%, and the C max and C min decreased by 69% and 89%, respectively (34).
273
When combined with rifabutin, rilpivirine AUC 24 decreased by 46%, and the C max and C min 274 decreased by 35% and 49%, respectively (7).
275
In conclusion, rifampicin was shown to be a more potent inducer of lersivirine metabolism 276 compared with rifabutin; therefore lersivirine should not be co-administered with rifampicin.
277
No dose adjustment is necessary for rifabutin in the presence of lersivirine; however, an were analyzed using a mixed-effect model with sequence, period, and treatment as fixed effects, and subject within sequence as a random effect. were analyzed using a mixed-effect model with sequence, period, and treatment as fixed effects, and subject within sequence as a random effect. 
